BlackRock Portfolio Management LLC's Schedule 13G Filing for Anika Therapeutics Inc

BlackRock Portfolio Management LLC has filed a Schedule 13G with the SEC, disclosing its beneficial ownership of 793,359 shares of Anika Therapeutics Inc's common stock, representing 5.5% of the total outstanding shares. The filing indicates that BlackRock has sole voting power over 769,931 shares and sole dispositive power over all 793,359 shares. The filing is made under Rule 13d-1(b) and includes certifications that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing the control of the issuer. The filing also includes details about the issuer, Anika Therapeutics Inc, and the reporting person, BlackRock Portfolio Management LLC.